CDS that clinicians actually trust.
80%+ of CDS alerts are ignored — because existing systems fire too many false alarms, provide no source attribution, and offer no way to assess how confident an alert is. Skippy Clinical delivers ECE-calibrated recommendations with full evidence tracing, patient-context-adjusted pathways, and FHIR R4 native output at sub-100ms latency.
Most major guidelines now prefer DOACs over warfarin in patients ≥75 with AF due to lower intracranial hemorrhage risk. If warfarin selected: initiate 2–5 mg/day, INR target 2.0–3.0, check within 3 days.
What a response looks like
Clinical query with reasoning trace, patient-context pathway analysis, and drug-condition evidence ranking — three capabilities, one API.
In patients ≥75 with AF, warfarin remains effective but bleeding risk is substantially elevated. Target INR 2.0–3.0. Most major guidelines (ACC/AHA 2023, ESC 2020) now prefer DOACs (apixaban, rivaroxaban) over warfarin in this population due to lower intracranial hemorrhage rates. If warfarin is selected: initiate at 2–5 mg daily, check INR within 3 days, and increase monitoring frequency until stable. CHA₂DS₂-VASc and HAS-BLED scoring before initiation.
Simulated output representative of real API responses. ECE-calibrated confidence scores. Findings sourced from ACC/AHA, FDA Labels, ADA, PubMed, and 50+ additional sources.
Six capabilities. One API.
Clinical query
Submit any clinical question and receive a source-attributed, ECE-calibrated answer. Persona-aware responses for clinician, researcher, student, and patient audiences. Returns confidence score, finding count, reasoning trace, and related topics. Target latency: <100ms.
Drug-condition evidence ranking
Retrieve ranked evidence for a drug-condition pair, filtered by minimum confidence. Each finding returns its confidence score, source, and evidence layer (L1 foundational / L2 supported / L3 clinical). Overall confidence aggregated across the evidence set.
Patient-context pathway analysis
Analyze a drug's mechanism pathway adjusted for a specific patient — age, conditions, current medications. Returns pathway steps with per-step confidence, flagged drug-drug interactions with severity scores, contraindications, and overall risk (LOW / MODERATE / HIGH).
FHIR R4 MedicationKnowledge
Return a structured FHIR R4 MedicationKnowledge resource for any drug — RxNorm coding, synonyms, intended routes, and confidence-annotated metadata. Ready for Epic CDS Hooks order-select and SMART on FHIR app launch contexts.
Entity deep-dive
Retrieve all findings about any clinical entity — drug, condition, mechanism, or biomarker. Findings grouped by type (definition, function, clinical, interaction, contraindication) with per-finding source attribution and confidence.
Clinical narrative generation
Generate a patient-or-professional clinical narrative from ranked evidence. Audience-aware prose with embedded confidence and source citations — useful for discharge summaries, patient education, and guideline synopses.
12 medical specialties. One evidence base.
Guidelines from ACC/AHA, IDSA, NCCN, ADA, USPSTF, and 10+ specialty societies — continuously indexed and attributed. Every recommendation traces back to its source document, version, and effective date.
ACC/AHA heart failure staging, AF anticoagulation, QTc monitoring
NCCN treatment protocols, checkpoint inhibitor toxicity, tumor board support
IDSA antibiotic selection, resistance patterns, empirical coverage
ADA diabetes management, thyroid dosing, adrenal insufficiency
eGFR-adjusted dosing, CKD staging, dialysis medication guidance
Epilepsy drug interactions, stroke prophylaxis, Parkinson's management
COPD step therapy, asthma biologics, inhaler technique guidance
DMARD selection, biologics monitoring, steroid tapering
Antipsychotic switching, SSRI titration, drug-drug interactions in polypharmacy
Beers Criteria flagging, fall-risk medications, age-adjusted dosing
Weight-based dosing, pediatric-specific formulations, off-label guidance
Anticoagulation management, transfusion thresholds, bleeding disorder protocols
Clinicians override 80–95% of drug-allergy and drug-interaction alerts in most hospital systems. The alerts that matter get lost in the noise — and the ones that fire incorrectly train clinicians to dismiss everything.
Skippy Clinical addresses alert fatigue at the source: ECE-calibrated confidence scores let clinicians see exactly how certain a recommendation is, full source attribution lets them verify it, and patient-context awareness reduces false alarms by adjusting for age, renal function, and current medications before an alert fires.
“A CDS system that says 'high confidence' on 90% of alerts — regardless of actual accuracy — provides no useful signal. Calibration means the confidence score predicts accuracy. ECE < 0.10 means a 0.85 score is right 85% ± 10% of the time.”
Expected Calibration Error is reported on every Skippy Clinical response alongside the confidence score. Clinicians and system administrators can audit calibration performance over time — and trust is earned through transparent measurement, not assertions.
EHR vendors, health systems, and specialty clinics
Built for regulated clinical AI deployment
ECE-calibrated confidence scores align with FDA SaMD AI/ML guidance requirements for performance transparency. Source attribution and tamper-evident audit trails satisfy Joint Commission medication safety standards and ONC HTI-1 predictive decision support documentation requirements.
FHIR R4 native output aligns with CMS-0057-F prior authorization requirements. SMART on FHIR launch context supported for Epic and Cerner. HIPAA-ready with BAA available. FDA 510(k) clearance pathway underway (Class II SaMD).
SOC 2 Type II certification targeted Q4 2026. Full reasoning trace and finding provenance retained per response for audit and accreditation purposes.
Often deployed together
Drug-drug interaction checking feeds directly into Clinical pathway analysis — severity-scored interaction pairs are surfaced in patient-context pathway responses before an order is placed.
Genetic factors are patient context. CYP2C19 diplotype affects warfarin dosing, clopidogrel activation, and SSRI metabolism — PGx results feed Clinical pathway analysis for genotype-adjusted recommendations.
Clinical documentation that drives coding accuracy. Structured diagnoses and procedures extracted from clinical notes feed downstream CPT+ICD-10 medical necessity verification.
Skippy Clinical is a decision-support tool for qualified healthcare professionals. It does not replace physician judgment, pharmacist review, or institutional clinical protocols. All recommendations should be confirmed against current clinical guidelines, patient-specific factors, and applicable institutional policies before clinical action. FDA 510(k) clearance in progress; not yet cleared as a medical device. HIPAA-ready; BAA available.
See Clinical in your EHR workflow
We work with EHR vendors, health systems, and specialty clinics. Let's talk about your clinical decision support problem.